Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg), covering 2023-11-21 to 2023-11-21. Get the full timeline:
Most recent: Clinical Trial Update: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) [Phase 3]